The global actinic keratosis (AK) treatment market is projected for significant growth, with estimated sales of USD 6,128.2 million in 2024, set to more than double to USD 12,282.4 million by 2034. This expansion is forecast to follow a compound annual growth rate (CAGR) of 7.2% from 2024 to 2034.
Incidences of skin cancers have become a major industry driver. By providing early treatment like actinic keratosis, absolute improvements in patience were seen in recent years. For instance, the United States recorded 59,170 cases of melanoma in men and 41,470 among women in the first quarter of 2024.
Significant investment in research and development operations to provide innovative medicines with easier dosing, enhanced efficacy, and lower prices provide the appealing potential for individuals in the actinic keratosis treatment industry.
Alternative treatments are expected to hamper industry potential during the forecast horizon. With the availability of over-the-counter medications, individuals are actively choosing these types of affordable and temporary treatment options for recovery. Moreover, the lack of skilled medical professionals is emerging as a significant industry barrier in underdeveloped countries.
The high cost of treatment is setting up major barriers to sector growth. Treatments such as cryotherapy sessions and other topical medications can lead to the requirement of high out-of-pocket expenses. As a result, this financial burden is discouraging patients and limiting awareness of treatment options among individuals.
Growth Drivers
- Increasing Prevalence of Skin Cancer: Actinic keratosis, a precancerous skin condition, has seen a rise in incidence due to prolonged exposure to ultraviolet (UV) radiation. The growing awareness of its potential to progress into invasive skin cancer (especially squamous cell carcinoma) is fueling demand for effective treatment solutions.
- Advances in Treatment Technologies: Recent developments in the treatment of actinic keratosis, such as the introduction of novel topical therapies, photodynamic therapy, and laser treatments, are contributing to market growth. These innovations offer better efficacy, improved patient outcomes, and fewer side effects compared to traditional treatment methods.
- Rising Awareness and Early Detection: As the global focus on skin cancer prevention intensifies, both healthcare professionals and patients are increasingly seeking early intervention treatments for actinic keratosis. Early detection and treatment can prevent progression to more severe forms of skin cancer, which is driving up the demand for treatments.
- Government Initiatives and Regulations: Governments worldwide are increasingly prioritizing skin cancer prevention and awareness campaigns. These initiatives, alongside the establishment of regulatory frameworks for novel therapies, are boosting the adoption of actinic keratosis treatments.
Regional Outlook
- North America: North America, particularly the United States, is expected to be the largest regional market due to the high incidence of actinic keratosis, especially among the aging population. Advanced healthcare infrastructure and increasing awareness regarding skin cancer are major drivers in the region.
- Europe: Europe is also expected to see significant market growth, driven by similar trends of increasing skin cancer prevalence and the introduction of new therapies. The European market is also supported by strong healthcare policies and dermatology expertise.
- Asia-Pacific: The Asia-Pacific region is anticipated to witness rapid growth in the actinic keratosis treatment market. With rising healthcare awareness, improving access to dermatological care, and an aging population, countries like Japan, China, and India are expected to see an increase in demand for AK treatments.
Get Complete Full Report
Future Outlook
The actinic keratosis treatment market is poised to experience substantial growth over the next decade. With the increasing global prevalence of skin cancer, advancements in treatment technologies, and growing awareness of the importance of early detection, the market is expected to expand at a CAGR of 7.2% from 2024 to 2034, reaching a market value of US$ 12,282.4 million by the end of the forecast period.
Key Insights
The actinic keratosis treatment market is experiencing growth due to several factors:
- Increasing Incidence of Skin Cancer: The rising prevalence of actinic keratosis, which can lead to skin cancer, is driving demand for effective treatment options.
- Technological Advancements: Innovations in treatment modalities and the development of novel therapeutics are enhancing the effectiveness of actinic keratosis treatments.
Growth Drivers
Several factors contributing to the market’s expansion include:
- Awareness Campaigns: Increased awareness about the risks associated with actinic keratosis and its potential progression to skin cancer is prompting more individuals to seek treatment.
- Regulatory Approvals: The growing number of product approvals from regulatory authorities is facilitating market growth. For instance, recent approvals for new therapies have expanded treatment options available to patients.
Competitive Landscape
By developing effective and innovative treatment options, key actinic keratosis treatment market players are ready to gain a major industry share in the current period. Several key players are authenticating their treatment by getting government approvals to gain consumer trust. Moreover, pharmaceutical industry players are playing a major role in the industry by developing and supplying essential drugs and medicines.
Strategies for stakeholders to unlock industry potential
- Developing innovative products with efficiency and safety
- Creating a competitive pricing strategy
- Implementing marketing and promotional activities
- Expanding geographically for better revenue growth
Recent Development
- In 2024 , Torqur AG, a leading clinical-stage pharmaceutical company, announced that the first patient has been dosed in the Phase 2 clinical trial of Bimiralisib for the treatment of Actinic Keratosis. Actinic Keratosis is a common skin condition that affects millions of people worldwide and is typically caused by overexposure to sunlight. Bimiralisib is a novel, highly selective, and potent PI3Kδ inhibitor that has shown promising results in pre-clinical studies. The Phase 2 clinical trial aims to evaluate the safety and efficacy of Bimiralisib in patients with Actinic Keratosis and is expected to enroll approximately 200 patients across multiple centers in Europe and the United States. This milestone marks a significant step forward in the development of Bimiralisib and brings hope to those suffering from Actinic Keratosis.
- In 2024, Biofrontera Inc, a biopharmaceutical company specializing in the treatment of skin disorders, filed a supplemental New Drug Application (sNDA) for an increased dosage of Aminolevulinic Acid Hydrochloride (ALA HCl) for the treatment of Actinic Keratosis (AK). AK is a common skin condition caused by long-term sun exposure that can lead to the development of skin cancer if left untreated. ALA HCl is a photosensitizing agent used in photodynamic therapy to destroy precancerous and cancerous skin cells selectively. The sNDA requests the approval of an increased dosage of ALA HCl from 20% to 30% for the treatment of AK. This filing marks an important milestone for Biofrontera as it seeks to expand the treatment options for patients with AK.
- In 2022, Jupiter Wellness completed recruitment for the JW-200 clinical trial. This uses a combination of aspartame and cannabidiol to provide quick relief and effectiveness for AK lesions and as a treatment for skin cancer. This treatment is a dual mechanism of action cox-2 inhibitor, and the completion of this trial is a significant step for the company in bringing this potentially groundbreaking treatment to market.
Key Companies Profiled
3M Health Care Ltd.; Alma Lasers Ltd.; Biofrontera AG; Bausch Health Companies Inc.; CryoConcepts LP; Cutera Inc.; DUSA Pharmaceuticals, Inc.; Galderma S.A.; LEO Pharma A/S; Novartis AG; Sun Pharmaceutical Industries Ltd.; Valeant Pharmaceuticals International, Inc.
Key Segments
By Treatment Type:
Depending on the treatment type, the industry is categorized into a topical treatment and procedural modality. The topical treatment category is further divided into 5-fluorouracil cream, diclofenac gel, imiquimod cream, and ingenol mebutate gel. Also, procedural modality is divided into chemical peels, cryotherapy, photodynamic therapy, and others.
By Disease Type:
The actinic keratosis treatment is effective in clinical and subclinical disease types.
By End User:
The key end-user industries are hospitals, private dermatology clinics, laser therapy centers, cancer treatment centers, spas and rejuvenation centers, and home care.
By Region:
Regional analysis is conducted of the industry in North America, Latin America, Europe, South Asia, East Asia, and Oceania, as well as the Middle East and Africa.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
